JosÉ Jimeno

Biography

DR. JOSÉ JIMENO IS A SEASONED MEDICAL ONCOLOGIST, WHO ALSO HOLDS A PH.D. FROM THE UNIVERSITY OF BARCELONA, AND LEADS THE COMPANY'S CLINICAL DEVELOPMENT PROGRAM. HE HAS HAD A FOCUS IN DRUG DEVELOPMENT FOR OVER TWENTY YEARS. FORMERLY VP OF CLINICAL AND SCIENTIFIC DEVELOPMENT AT PHARMAMAR, HE WAS RESPONSIBLE FOR THE INTEGRATED DEVELOPMENT OF YONDELIS®, WHICH IS APPROVED IN THE U.S., THE E.U., JAPAN, AND MORE THAN 60 OTHER COUNTRIES FOR THE TREATMENT OF OVARIAN CANCER AND SARCOMA. HIS PRIOR INDUSTRY ROLES INCLUDE WORK AT FARMITALIA CARLO ERBA AND US BIOSCIENCES, WHERE HE FOCUSED ON NOVEL COMPOUNDS IN THE ANTHRACYCLINE AND ANTI-METABOLITE THERAPEUTIC CLASSES. MOST RECENTLY, DR. JIMENO WAS CO-FOUNDER AND CEO OF PANGAEA BIOTECH, A CANCER DIAGNOSTICS COMPANY FOCUSED ON PERSONALIZED MEDICINE, WHERE HE WAS INVOLVED IN THE DEVELOPMENT OF THE EGFR MUTATION DIAGNOSTIC APPROVED BY THE FDA FOR USE IN NSCLC CANCER PATIENTS. DR. JIMENO HAS PUBLISHED OVER 100 PAPERS IN PEER REVIEW JOURNALS ON CANCER, AND IS A GUEST LECTURER IN IMMUNOLOGY AT THE UNIVERSITY OF ZARAGOZA. 

Research Interest

NOVEL COMPOUNDS IN THE ANTHRACYCLINE AND ANTI-METABOLITE THERAPEUTIC CLASSES